$8.33
0.060.73%
最終更新: Sep 30, 4:40 PM
$8.39
0.121.49%
Benzinga
Benzinga
Benzinga
木曜日, 10 01
Benzinga
© 2026 Benzinga | All Rights Reserved
BioCryst Pharma (BCRX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
BioCryst Pharma (BCRX) は、8 5, 2026日にfiscal yearの2026に関するガイダンスを直近で発表しました。同社は当期の売上高を$635M - $660Mの範囲と予想しています。
以前のガイダンスと比較して、BioCryst Pharmaは売上高予測を以前の範囲である維持から$635M - $660Mに引き上げました。
BioCryst Pharmaは、11から1 10, 2025の間に8 5, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 4 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.22 | $0.10 | $0.07 | $0.08 |
| Actual | $0.30 | $0.14 | $0.06 | $0.16 |
| Surprise | +36.4% | +40.0% | -21.4% | +100.0% |
| Revenue | ||||
| Estimate | $187.8M | $152.2M | $150.5M | $162.2M |
| Actual | $218.3M | $156.4M | $163.3M | $159.4M |
| Surprise | +16.2% | +2.79% | +8.46% | -1.76% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.11 | $0.13 | $0.07 | $0.11 |
| Revenue | ||||
| Consensus | $165.5M | $169.1M | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $0.30 | $0.22 | 36.4 % |
| Q1 | May 6, 2026 | $0.14 | $0.10 | 40.0 % |
| Q4 | Feb 26, 2026 | $0.06 | $0.07 | -21.4 % |
| Q3 | Nov 3, 2025 | $0.16 | $0.08 | 100.0 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $218.25M | $187.77M | 16.2 % |
| Q1 | May 6, 2026 | $156.41M | $152.16M | 2.79 % |
| Q4 | Feb 26, 2026 | $163.28M | $150.54M | 8.46 % |
| Q3 | Nov 3, 2025 | $159.40M | $162.24M | -1.76 % |